ArticleVascular health and risk management2026
Evaluation of Prothrombin Time and Activated Partial Thromboplastin Time in Antithrombotic-Treated Cardiac Patients: A Cross-Sectional Study from Sana'a City, Yemen.
Article in Vascular health and risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antithrombotic therapy is a cornerstone of managing cardiac diseases, necessitating routine monitoring of coagulation parameters like Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT). Data on the coagulation profiles of treated patients in resource limited settings like Yemen are scarce. Objective: This study aimed to evaluate PT and APTT in antithrombotic-treated cardiovascular patients and assess their variation across different cardiac diagnoses and therapy regimens in Sana'a, Yemen. Methods: A cross-sectional study was conducted on 200 cardiovascular patients on antithrombotic therapy at selected hospitals in Sana'a City between January and March 2024. Demographic, clinical, and therapeutic data were collected. Coagulation parameters (PT, INR, APTT) were measured and compared across diagnostic groups and treatment types using Kruskal-Wallis and Mann-Whitney Results: The study group was predominantly male (69.0%), aged 51-80 years (57.0%). Coagulation parameters varied significantly across cardiac diagnoses (p <0.01 for PT, INR, APTT). Patients with Mitral Valve Replacement (MVR) had the highest median PT (36.45s) and INR (2.75). Post-hoc analysis confirmed MVR patients had significantly elevated parameters compared to other groups (e.g. PT 19.01s higher than Segment Elevation Myocardial Infarction (STEMI), p=0.003). Rheumatic Heart Disease (RHD) patients showed intermediate PT elevation. No significant differences were found between STEMI and Non-ST-segment Elevation - Acute Coronary Syndrome (NSTE-ACS) subtypes. Antithrombotic type significantly influenced results: warfarin patients had the highest median PT (20.00s), INR (1.53), and APTT (40.00s) (p<0.05). Dosage analysis confirmed warfarin's significant impact compared to aspirin doses. Conclusion: Coagulation profiles in cardiovascular patients vary significantly according to both the underlying cardiac diagnosis and the type of antithrombotic therapy. MVR and RHD patients display notably elevated parameters, while ACS subtypes show similar profiles. These findings underscore the need for diagnosis-specific monitoring strategies and confirm the expected pharmacological effects of different antithrombotic agents in a Yemeni population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.